A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours

A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.1007/s00280-020-04225-7
Journal or Publication Title: Cancer Chemotherapy and Pharmacology
Volume: 87
Number: 5
Page Range: pp. 613-620
Date: 2021
Divisions: ACRF Centenary Cancer Research Centre
Depositing User: General Admin
Identification Number: 10.1007/s00280-020-04225-7
ISSN: 0344-5704
Date Deposited: 10 Jun 2021 06:10
Abstract:

Purpose: This phase I study was conducted to evaluate the safety and Maximum Tolerated Dose of PENAO (4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid), a second-generation organic arsenical with anti-mitochondrial activity, when given as a continuous intravenous infusion (CIVI), in patients with advanced solid tumours.

Methods: Eligibility criteria for this trial included age ≥ 18 years, advanced solid tumour, ECOG Performance Status ≤ 1 and adequate organ function. PENAO was administered by CIVI, with dose levels initially increased by infusion duration in a 21-day cycle at a fixed daily dose and then increased daily dose. Standard dose-limiting toxicity (DLT) definitions were used in a "3 + 3" design. Patients had regular monitoring of toxicity and efficacy. Pharmacokinetic assays of serum and urine As were performed.

Results: Twenty-six patients were treated across 8 dose levels. The only dose-limiting toxicity (DLT) observed was fatigue, that occurred in one patient treated at the highest dose level of 9 mg/m2/day. No significant organ toxicity or objective responses were observed, although there were two patients with stable disease lasting up to 7 months. Pharmacokinetic analysis unexpectedly indicated a half-life of 9-19 days, invalidating the CIVI dosing resulting in discontinuation of the study before the RP2D was defined.

Conclusions: PENAO was administered by CIVI at dose levels up to 9 mg/m2/day with only one DLT noted. Pharmacokinetic studies invalidated the rationale for continuous dosing and led to discontinuation of the trial without defining a RP2D. Future clinical development of PENAO will use intermittent dosing schedule, alone and in combination with rapamycin.

Creators:
Creators
Email
Sarkar, Sunit
UNSPECIFIED
Tran, Ben
UNSPECIFIED
Horvath, Lisa
UNSPECIFIED
Lam, Michael
UNSPECIFIED
Savas, Peter
UNSPECIFIED
Grimison, Peter
UNSPECIFIED
Whittle, James R.
UNSPECIFIED
Kuo, James C.
UNSPECIFIED
Signal, Nicole
UNSPECIFIED
Edmonds, David
UNSPECIFIED
Hogg, Philip
UNSPECIFIED
Rischin, Danny
UNSPECIFIED
Desai, Jayesh
UNSPECIFIED
Hamilton, Anne
UNSPECIFIED
Last Modified: 10 Jun 2021 06:10
URI: https://eprints.centenary.org.au/id/eprint/1038

Actions (login required)

View Item View Item